Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LH-1802
- Development stage
- Phase 1
- Lead developer
- Jiangsu Lianhuan Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LH-1802 is an orally bioavailable small molecule inhibitor of the Menin-KMT2A (formerly MLL1) protein-protein interaction. Developed by Jiangsu Lianhuan Pharmaceutical, it is currently in Phase 1 clinical development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The therapeutic rationale focuses on patients with KMT2A rearrangements (KMT2Ar) or NPM1 mutations, where the Menin-KMT2A complex drives the expression of HOXA and MEIS1 genes, maintaining a leukemic state. By competitively binding to Menin, LH-1802 disrupts this complex, leading to the downregulation of leukemogenic genes and inducing the differentiation of myeloid blasts.
02
Targets
MEN1 (Menin)KMT2A
Beyond the preview
Go deeper on LH-1802.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LH-1802.